Editas is a cash-backed CRISPR “deep value option” pivoting to in vivo LDLR upregulation—one strong human readout could re-rate the stock, one miss could strand it as a patent shell.
Overview
Editas Medicine is at a late-2025 inflection point after a radical strategic reset. Once a flagship CRISPR company with broad ambitions (including ex vivo cell therapies), it has pivoted into a streamlined, pure-play in vivo gene editing company following the late-2024 discontinuation of reni-cel in SCD/TDT—an explicit decision to avoid value destruction as a third-to-market, capital-intensive autologous therapy behind established competitors (Casgevy, Lyfgenia). The market prices EDIT like a distressed asset (~$2.17/share), implying an enterprise value around ~$46M after netting ~$165.6M cash, effectively assigning near-zero value to the in vivo pipeline and discounting the IP estate. Yet the company has stabilized financially via burn reduction, non-dilutive financing (notably monetizing part of Vertex-related receivables through DRI Healthcare), and ongoing milestone-driven partner revenue (e.g., BMS). The rebuilt thesis centers on EDIT-401, a liver-directed in vivo program for hypercholesterolemia using AsCas12a to upregulate LDLR directly—distinct from PCSK9 knockdown/base-edit strategies—and supported by clinically validated LNP delivery licensed from Genevant. Editas also retains a potentially valuable IP licensing model as the exclusive licensee for foundational Broad CRISPR patents, creating an event-driven, asymmetric setup: the stock is cash-backed with significant upside if EDIT-401 translates clinically, but meaningful existential risks remain.